Exploring the Active Site of the Antibacterial Target MraY by Modified Tunicamycins.

Jenny Hering, Elin Dunevall, Arjan Snijder, Per-Olof Eriksson, Michael A Jackson, Trina M Hartman, Ran Ting, Hongming Chen, Neil P J Price, Gisela Brändén, Margareta Ek

ACS chemical biology 2020 Nov 20

filter terms:

The alarming growth of antibiotic resistance that is currently ongoing is a serious threat to human health. One of the most promising novel antibiotic targets is MraY (phospho-MurNAc-pentapeptide-transferase), an essential enzyme in bacterial cell wall synthesis. Through recent advances in biochemical research, there is now structural information available for MraY, and for its human homologue GPT (GlcNAc-1-P-transferase), that opens up exciting possibilities for structure-based drug design. The antibiotic compound tunicamycin is a natural product inhibitor of MraY that is also toxic to eukaryotes through its binding to GPT. In this work, we have used tunicamycin and modified versions of tunicamycin as tool compounds to explore the active site of MraY and to gain further insight into what determines inhibitor potency. We have investigated tunicamycin variants where the following motifs have been modified: the length and branching of the tunicamycin fatty acyl chain, the saturation of the fatty acyl chain, the 6″-hydroxyl group of the GlcNAc ring, and the ring structure of the uracil motif. The compounds are analyzed in terms of how potently they bind to MraY, inhibit the activity of the enzyme, and affect the protein thermal stability. Finally, we rationalize these results in the context of the protein structures of MraY and GPT.

Citation

Jenny Hering, Elin Dunevall, Arjan Snijder, Per-Olof Eriksson, Michael A Jackson, Trina M Hartman, Ran Ting, Hongming Chen, Neil P J Price, Gisela Brändén, Margareta Ek. Exploring the Active Site of the Antibacterial Target MraY by Modified Tunicamycins. ACS chemical biology. 2020 Nov 20;15(11):2885-2895